logo

G1 Therapeutics, Inc. (GTHX)



Trade GTHX now with
  Date
  Headline
6/18/2019 6:05:37 AM G1 Therapeutics Announces Updated Results From Phase 2 Trial Of Trilaciclib In Combination With Chemotherapy
6/13/2019 7:06:51 AM G1 Therapeutics Announces Updates To Board Of Directors; Garry Nicholson To Serve As New Board Chair
4/30/2019 9:39:40 AM Wedbush Reiterates G1 Therapeutics, Inc. (GTHX) At Outperform With $67 Price Target
3/1/2019 7:03:52 AM Wedbush Is Cutting G1 Therapeutics, Inc. (GTHX) FY19 Estimate To -2.74 From -2.18
3/1/2019 7:03:29 AM Wedbush Is Lowering G1 Therapeutics, Inc. (GTHX) Q4 19 Estimate To -0.74 From -0.55
3/1/2019 7:03:19 AM Wedbush Is Cutting G1 Therapeutics, Inc. (GTHX) Q3 19 Estimate To -0.70 From -0.55
3/1/2019 7:03:05 AM Wedbush Is Cutting G1 Therapeutics, Inc. (GTHX) Q2 19 Estimate To -0.66 From -0.54
3/1/2019 7:02:45 AM Wedbush Is Lowering G1 Therapeutics, Inc. (GTHX) Q1 19 Estimate To -0.64 From -0.54
3/1/2019 7:01:57 AM Wedbush Reiterates G1 Therapeutics, Inc. (GTHX) At Outperform With $67 Price Target
12/20/2018 6:41:49 AM Wedbush Reiterates G1 Therapeutics, Inc. (GTHX) At Outperform With $67 Price Target
12/4/2018 6:58:56 AM G1 Announces Preliminary Anti-tumor Efficacy And Myelopreservation Data From Phase 2 Trial Evaluating Trilaciclib
11/8/2018 1:23:56 PM Wedbush Is Increasing G1 Therapeutics, Inc. (GTHX) 2019 Estimate To -2.18 From -2.72
11/8/2018 1:23:46 PM Wedbush Is Raising G1 Therapeutics, Inc. (GTHX) 4Q19 Estimate To -0.55 From -0.68
11/8/2018 1:23:35 PM Wedbush Is Raising G1 Therapeutics, Inc. (GTHX) 3Q19 Estimate To -0.55 From -0.68